Volume 20, Number 7—July 2014
Research
Changes in Capsule and Drug Resistance of Pneumococci after Introduction of PCV7, Japan, 2010–2013
Figure 3
![Proportional yearly changes in macrolide resistance according to resistance genes erm(B) and mef(A) identified by real-time PCR, Japan, April 2010–March 2013. The percentage of each resistance gene was calculated from the number of Streptococcus pneumoniae strains for each year. VT, vaccine serotype (serotypes 4, 9V, 18C, 6B, 14, 19F, 23F) included in the 7-valent pneumococcal vaccine; NVT, serotypes not included in the 7-valent pneumococcal conjugate vaccine; MLS, macrolide-susceptible strains](/eid/images/13-1485-F3.jpg)
Figure 3. Proportional yearly changes in macrolide resistance according to resistance genes erm(B) and mef(A) identified by real-time PCR, Japan, April 2010–March 2013The percentage of each resistance gene was calculated from the number of Streptococcus pneumoniae strains for each yearVT, vaccine serotype (serotypes 4, 9V, 18C, 6B, 14, 19F, 23F) included in the 7-valent pneumococcal vaccine; NVT, serotypes not included in the 7-valent pneumococcal conjugate vaccine; MLS, macrolide-susceptible strains not possessing any resistance gene; MLR-mef(A), macrolide-resistant strain possessing the mef(A) gene; MLR-erm(B), macrolide-resistant strain possessing the erm(B) gene; MLR-mef(A)+erm(B), macrolide-resistant strain possessing both mef(A) and erm(B) genes.